Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for repotrectinib, a next-generation tyrosine kinase inhibitor, as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer and for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion, and who have received a prior NTRK inhibitor, or have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted. The European Commission, which has the authority to approve medicines for the European Union, will now review the CHMP recommendation. The final EC decision is expected in January 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story
- Bristol Myers initiated with a Peer Perform at Wolfe Research
- Bristol Myers Squibb put volume heavy and directionally bearish
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
- Bristol Myers price target raised to $61 from $57 at BMO Capital